These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32894506)

  • 21. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2.
    Miyataka M; Rich KA; Ingram M; Yamamoto T; Bing RJ
    Hypertension; 2002 Mar; 39(3):785-9. PubMed ID: 11897764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Fiorucci S; Meli R; Bucci M; Cirino G
    Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Biology of Prostanoids and Drug Discovery.
    Zhu L; Zhang Y; Guo Z; Wang M
    Arterioscler Thromb Vasc Biol; 2020 Jun; 40(6):1454-1463. PubMed ID: 32295420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
    Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
    J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
    Skarke C; Alamuddin N; Lawson JA; Cen L; Propert KJ; Fitzgerald GA
    Clin Pharmacol Ther; 2012 Jun; 91(6):986-93. PubMed ID: 22278334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New nonsteroidal anti-inflammatory agents: nitric oxide donors and selective cyclooxygenase-2 inhibitors].
    Bannwarth B; Berenbaum F
    Rev Med Interne; 1999 Aug; 20 Suppl 3():341s-345s. PubMed ID: 10480184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostanoids in nociception and pain.
    Zeilhofer HU
    Biochem Pharmacol; 2007 Jan; 73(2):165-74. PubMed ID: 16959219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandins and leukotrienes: advances in eicosanoid biology.
    Funk CD
    Science; 2001 Nov; 294(5548):1871-5. PubMed ID: 11729303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostacyclin among prostanoids.
    Gryglewski RJ
    Pharmacol Rep; 2008; 60(1):3-11. PubMed ID: 18276980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
    Celotti F; Laufer S
    Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclooxygenase-2 biology.
    Clària J
    Curr Pharm Des; 2003; 9(27):2177-90. PubMed ID: 14529398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations.
    FitzGerald GA
    Am J Cardiol; 2002 Mar; 89(6A):26D-32D. PubMed ID: 11909558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
    Lehmann FS; Beglinger C
    Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility.
    Cronstein BN
    Cleve Clin J Med; 2002; 69 Suppl 1():SI13-9. PubMed ID: 12086289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in inducible cyclooxygenase (COX-2) inhibition.
    de Leval X; Delarge J; Somers F; de Tullio P; Henrotin Y; Pirotte B; Dogné JM
    Curr Med Chem; 2000 Oct; 7(10):1041-62. PubMed ID: 10911017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.